Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas

Ruiz,María Fernanda; Gennaro,María Verónica; Bastone,Laura C.; Godoy,Alicia R.; Torruella,Mónica; Perez,Germán R.

doi:10.3892/mco.2021.2312

Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas

Authors:
- María Fernanda Ruiz
- María Verónica Gennaro
- Laura C. Bastone
- Alicia R. Godoy
- Mónica Torruella
- Germán R. Perez
View Affiliations

Affiliations: Center for Pathological Diagnosis SRL (Gamma Group), Rosario, Santa Fe 2000, Argentina, Department of Molecular Diagnostics, Gammalab/Private Hospital of Rosario (Gamma Group), Rosario, Santa Fe 2000, Argentina
Published online on: May 31, 2021 https://doi.org/10.3892/mco.2021.2312
Article Number: 150

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the impact caused by the 2016 World Health Organization (WHO) diagnostic classification of gliomas in 139 patients studied in Argentina. Formalin‑fixed paraffin‑embedded tissues were used for histological and immunohistochemical analysis [glial fibrillary acidic protein, KI67, synaptophysin and isocitrate dehydrogenase (IDH)1‑R132H]. DNA from formalin‑fixed paraffin‑embedded tissues was used for molecular analysis: 1p/19q co‑deletion and mutation status of the IDH gene. These experiments were performed by direct Sanger sequencing and multiplex ligation‑dependent probe amplification. According to the new classification, diagnoses included oligodendroglioma IDH‑mutant and 1p/19q co‑deletion (4.20%), anaplastic oligodendroglioma IDH‑mutant and 1p/19q co‑deletion (2.52%), diffuse astrocytoma IDH‑mutant (6.72%), diffuse astrocytoma IDH‑wild type (1.68%), anaplastic astrocytoma IDH‑mutant (5.04%), anaplastic astrocytoma IDH‑wild type (8.40%), glioblastoma IDH‑mutant (5.88%) and glioblastoma IDH‑wild type (65.56%). Regarding tumor histology, 60% of oligodendrogliomas, 35% of astrocytoma and 100% of unclassified gliomas were re‑classified, while glioblastomas maintained their initial classification. Additionally, the present study evaluated the prognostic value of the histological grade for the 2007 and 2016 WHO classifications of gliomas. The histological subgroup associated with longer overall survival (OS) was grade II glioma (OS‑2007WHO, 35.6 months; and OS‑2016WHO, 47.7 months). Glioblastoma was the subgroup associated with a poor outcome (OS‑2007WHO, 10.4 months; and OS‑2016WHO, 11.1 months). The present study evaluated the OS of tumor grade subgroups with respect to their IDH status. For all subgroups, IDH‑mutant tumors were associated with an improved prognosis compared with IDH‑wild type tumors. The results suggested that the incorporation of molecular biomarkers in the new WHO classification improves tumor characterization and prognostic value of the subgroups.

View Figures

View References

1	Chen R, Smith-Cohn M, Cohen AL and Colman H: Glioma subclassifications and their clinical significance. Neurotherapeutics. 14:284–297. 2017.PubMed/NCBI View Article : Google Scholar
2	Wesseling P, Kros JM and Jeuken JWM: The pathological diagnosis of diffuse gliomas: Towards a smart synthesis of microscopic and molecular information in a multidisciplinary context. Diagnostic Histopathology. 17:486–494. 2011.
3	Kristensen BW, Priesterbach-Ackley LP, Petersen JK and Wesseling P: Molecular pathology of tumors of the central nervous system. Ann Oncol. 30:1265–1278. 2019.PubMed/NCBI View Article : Google Scholar
4	Brandner S and von Deimling A: Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathol Appl Neurobiol. 41:694–720. 2015.PubMed/NCBI View Article : Google Scholar
5	Diwanji TP, Engelman A, Snider JW and Mohindra P: Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther. 8:99–113. 2017.PubMed/NCBI View Article : Google Scholar
6	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007.PubMed/NCBI View Article : Google Scholar
7	Fuller GN and Scheithauer BW: The 2007 revised world health organization (WHO) classification of tumours of the central nervous system: Newly codified entities. Brain Pathol. 17:304–307. 2007.PubMed/NCBI View Article : Google Scholar
8	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016.PubMed/NCBI View Article : Google Scholar
9	Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, et al: International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 24:429–435. 2014.PubMed/NCBI View Article : Google Scholar
10	Iwamoto FM, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, Rosenblum M and Hormigo A: Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol. 88:293–298. 2008.PubMed/NCBI View Article : Google Scholar
11	Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, Capper D, Figarella-Branger D, Lopes MB, Wick W and van den Bent M: cIMPACT-NOW update 1: Not otherwise specified (NOS) and not elsewhere classified (NEC). Acta Neuropathol. 135:481–484. 2018.PubMed/NCBI View Article : Google Scholar
12	Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C and von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116:597–602. 2008.PubMed/NCBI View Article : Google Scholar
13	Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009.PubMed/NCBI View Article : Google Scholar
14	Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K and Delattre JY: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 27:4150–4154. 2009.PubMed/NCBI View Article : Google Scholar
15	Kouwenhoven MC, Kros JM, French PJ, Biemond-ter Stege EM, Graveland WJ, Taphoorn MJ, Brandes AA and van den Bent MJ: 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer. 42:2499–2503. 2006.PubMed/NCBI View Article : Google Scholar
16	Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, et al: Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: Use with caution. Mod Pathol. 26:922–929. 2013.PubMed/NCBI View Article : Google Scholar
17	Garman RH: Histology of the central nervous system. Toxicol Pathol. 39:22–35. 2011.PubMed/NCBI View Article : Google Scholar
18	Wiedenmann B, Franke WW, Kuhn C, Moll R and Gould VE: Synaptophysin: A marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci USA. 83:3500–3504. 1986.PubMed/NCBI View Article : Google Scholar
19	Choi BH and Khang SK: Immunohistochemical Expression of Synaptophysin in Brain Tumors. The Korean Journal of Pathology, 35: 433-439.
20	van den Bent MJ: Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinician's perspective. Acta Neuropathol. 120:297–304. 2010.PubMed/NCBI View Article : Google Scholar
21	Skotheim RI, Diep CB, Kraggerud SM, Jakobsen KS and Lothe RA: Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet Cytogenet. 127:64–70. 2001.PubMed/NCBI View Article : Google Scholar
22	Torres-Martin M, Pena-Granero C, Carceller F, Gutiérrez M, Burbano RR, Pinto GR, Castresana JS, Melendez B and Rey JA: Homozygous deletion of TNFRSF4, TP73, PPAP2B and DPYD at 1p and PDCD5 at 19q identified by multiplex ligation-dependent probe amplification (MLPA) analysis in pediatric anaplastic glioma with questionable oligodendroglial component. Mol Cytogenet. 7(1)2014.PubMed/NCBI View Article : Google Scholar
23	Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, et al: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol. 118:469–474. 2009.PubMed/NCBI View Article : Google Scholar
24	Schoonjans F, Zalata A, Depuydt CE and Comhaire FH: MedCalc: A new computer program for medical statistics. Comput Methods Programs Biomed. 48:257–262. 1995.PubMed/NCBI View Article : Google Scholar
25	Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, Jones DT, Pfister SM, Herold-Mende C, Wick W, et al: Farewell to oligoastrocytoma: In situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 128:551–559. 2014.PubMed/NCBI View Article : Google Scholar
26	Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, et al: Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol. 132:625–634. 2016.PubMed/NCBI View Article : Google Scholar
27	Iuchi T, Sugiyama T, Ohira M, Kageyama H, Yokoi S, Sakaida T, Hasegawa Y, Setoguchi T and Itami M: Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Brain Tumor Pathol. 35:71–80. 2018.PubMed/NCBI View Article : Google Scholar
28	Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, et al: cIMPACT-NOW update 3: Recommended diagnostic criteria for ‘Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.’. Acta Neuropathol. 136:805–810. 2018.PubMed/NCBI View Article : Google Scholar
29	Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, et al: Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 372:2499–2508. 2015.PubMed/NCBI View Article : Google Scholar
30	Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, et al: Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 129:679–693. 2015.PubMed/NCBI View Article : Google Scholar
31	Wijnenga MMJ, Dubbink HJ, French PJ, Synhaeve NE, Dinjens WNM, Atmodimedjo PN, Kros JM, Dirven CMF, Vincent AJPE and van den Bent MJ: Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: Assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol. 134:957–959. 2017.PubMed/NCBI View Article : Google Scholar
32	Preusser M, Wohrer A, Stary S, Hoftberger R, Streubel B and Hainfellner JA: Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol. 70:715–723. 2011.PubMed/NCBI View Article : Google Scholar
33	Losman JA and Kaelin WG Jr: What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 27:836–852. 2013.PubMed/NCBI View Article : Google Scholar
34	Ye D, Ma S, Xiong Y and Guan KL: R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell. 23:274–276. 2013.PubMed/NCBI View Article : Google Scholar
35	Bush NA and Butowski N: The effect of molecular diagnostics on the treatment of glioma. Curr Oncol Rep. 19(26)2017.PubMed/NCBI View Article : Google Scholar
36	Lipp ES and McLendon RE: Tissue is the issue: Biomarkers of prognosis and classification in adult gliomas. Semin Oncol Nurs. 34:430–442. 2018.PubMed/NCBI View Article : Google Scholar
37	Stoyanov GS, Dzhenkov DL, Kitanova M, Donev IS and Ghenev P: Correlation between Ki-67 index, World health organization grade and patient survival in glial tumors with astrocytic differentiation. Cureus. 9(e1396)2017.PubMed/NCBI View Article : Google Scholar